OncoMatch/Clinical Trials/NCT05648019

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Is NCT05648019 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anti-CD19 CAR T-cells for lymphoblastic leukemia.

Phase 2RecruitingKK Women's and Children's HospitalNCT05648019Data as of May 2026

Treatment: Anti-CD19 CAR T-cells — The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD19 tumour expression (expression demonstrated in bone marrow or peripheral blood within 3 months of study entry)

Documentation of CD19 tumour expression (e.g. by flow cytometry) demonstrated in bone marrow or peripheral blood within 3 months of study entry

Prior therapy

Min 2 prior lines

Must have received: systemic therapy — relapsed or refractory large B-cell lymphoma

Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

Lab requirements

Blood counts

adequate organ functions

Kidney function

adequate organ functions

Liver function

adequate organ functions

Cardiac function

adequate organ functions

Adequate organ functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify